Randomized controlled trial for the effect of HIF-PH inhibitor and epoetin beta pegol in renal anemia treatment of the peritoneal dialysis (PD) patients

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2020
INTERVENTION: Change of therapy from epoetin beta‐pegol to HIF‐PH inhibitor, followed by 12 weeks of treatment Continue treatment with epoetin beta‐pegol for 12 weeks CONDITION: Peritoneal dialysis patients PRIMARY OUTCOME: Transition of Hb, evaluated 12 weeks after assignment SECONDARY OUTCOME: Iron metabolism including hepcidin., evaluated 12 weeks after assignment INCLUSION CRITERIA:
Epistemonikos ID: 8d1e314b842b6150145596a03cdbf037938231de
First added on: Aug 24, 2024